Protective effect of notoginsenoside R1 on an APP/PS1 mouse model of Alzheimer's disease by up-regulating insulin degrading enzyme and inhibiting Aβ accumulation


BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:
2015
Contact PI Name:
Wensheng Zhang
Contact PI Affiliation:
Engineering Research Center of Natural Medicine, Ministry of Education, Beijing Normal University, Beijing, China
Co-Authors:
Zhi Li, Hang Li, Chunhui Zhao, Cui Lv, Changjia Zhong, Wenfeng Xin
Primary Reference (PubMED ID):
Funding Source:
National Natural Science Foundation of China
Key New Drug Creation and Development Program of China
Study Goal and Principal Findings:

This study aimed at exploring the anti-AD effects of Notoginsenoside R1 (NTR1)  in APP/PS1 Tg AD mice. Notoginsenoside R1 (NTR1) is the unique and main active ingredient of Panax notoginseng a well-known traditional Chinese herbal medicine which has been widely used for diseases related to the circulatory system, such as cardio- and cerebro-vascular disorders, and liver dysfunction.  The study found that mice treated with NTR1, showed significant amelioration in  cognitive function and increased choline acetyl transferase expression, as compared to the vehicle treated mice. NTR1 treatment inhibited Aβ accumulation and increased insulin degrading enzyme (IDE) expression in APP/PS1 mice, the latter suggests that NTR1 may exert its protective effects through the enhancement of the Aβ degradation. Data showed that the increased level of peroxisome proliferator-activated receptor γ (PPARγ) and the up-regulation of insulin degrading enzyme induced by NTR1 were inhibited by administration of GW9662 (a PPARγ antagonist), indicating that the effect of NTR1 was mediated, at least in part, by PPARγ.  These findings demonstrate that NTR1 has protective effect on AD mouse model and suggest that NTR1 may be a potential candidate for AD treatment.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Natural Product
Therapeutic Agent:
Notoginsenoside R1 (NTR1)
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
C57BL/6J

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest
Experiment Notes

PK studies, particularly BBB penetration, were reported in the following: Li L. Pharmacokinetic studies of notoginsenoside R1 and ginsenoside Rg1 of Jiedutongluo formulation in rat cerebrospinal fluid. Chin Pharmacol Bull 2014; 30(1): 126-31.

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Histopathology
beta Amyloid Load
Biochemical
Brain-beta Amyloid Peptide 40
Brain-beta Amyloid Peptide 42
Insulin Degrading Enzyme (IDE)
Peroxisome Proliferator-Activated Receptor gamma (PPAR gamma)
Immunochemistry
Choline Acetyltransferase (ChAT)
Pharmacokinetics
Blood Brain Barrier Penetration

Source URL: http://alzped.nia.nih.gov/protective-effect